Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CONTINUOUS-INFUSION OF 5-FLUOROURACIL BY DOUBLE ROUTE (INTRAVENOUS AND INTRAPERITONEAL) WITH MODULATION BY FOLINIC ACID - CLINICAL AND PHARMACOKINETIC, PHASE-I STUDY IN PATIENTS WITH INTRAABDOMINAL MALIGNANCIES
Autore:
DEFORNI M; GUALANO V; CANAL P; MARTEL P; IZARSOUM F; CHEVREAU C; SOULIE P; ROCHE H; BUGAT R;
Indirizzi:
CTR CLAUDIUS REGAUD,PHARMACOL CLIN & EXPTL MED ANTICANC GRP,20-24 RUEPONT ST PIERRE F-31052 TOULOUSE FRANCE
Titolo Testata:
Bulletin du cancer
fascicolo: 5, volume: 80, anno: 1993,
pagine: 408 - 417
SICI:
0007-4551(1993)80:5<408:CO5BDR>2.0.ZU;2-4
Fonte:
ISI
Lingua:
FRE
Soggetto:
METASTATIC COLORECTAL-CARCINOMA; HIGH-DOSE LEUCOVORIN; BIOCHEMICAL MODULATION; NECK-CANCER; FLUOROURACIL; CHEMOTHERAPY; CISPLATIN; COLON; TRIAL; HEAD;
Keywords:
FLUOROURACIL; INTRAVENOUS AND INTRAPERITONEAL CHEMOTHERAPY; CONTINUOUS INFUSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
M. Deforni et al., "CONTINUOUS-INFUSION OF 5-FLUOROURACIL BY DOUBLE ROUTE (INTRAVENOUS AND INTRAPERITONEAL) WITH MODULATION BY FOLINIC ACID - CLINICAL AND PHARMACOKINETIC, PHASE-I STUDY IN PATIENTS WITH INTRAABDOMINAL MALIGNANCIES", Bulletin du cancer, 80(5), 1993, pp. 408-417

Abstract

Thirteen patients with intra-abdominal malignancies entered a phase Istudy of fluorouracil (5-FU) given by continuous infusion (96 h) iv and ip, simultaneously, and modulated by high-dose folinic acid-iv. Severe but reversible stomatitis was the only dose-limiting toxicity at adose of 5-FU of 550 mg/m2/day. Local toxicity (5-FU-induced abdominalpain) was a significant side effect in patients receiving more than 1cycle. The pharmacokinetic advantage of 5-FU-ip was confirmed in our study (ratio AUC peritoneum/plasma between 160 and 328). The systemic exposure to 5-FU (plasmatic AUC ranging from 73.4 to 173.21 muM) and to AF were found in efficacious ranges. The recommended dose of 5-FU ivand ip is 500 mg/m2/day. This regimen is feasible and may potentiallyhave application for adjuvant chemotherapeutic programs after surgeryfor colorectal cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/11/20 alle ore 08:19:32